News

April 18, 2019April 18, 2019

Cortisol, ACTH Levels Identify Patients at Risk of Low Blood Potassium After Korlym Treatment, Study Says

News

Serum cortisol and adrenocorticotropic hormone (ACTH) levels may be useful in identifying Cushing’s syndrome patients at risk of experiencing low blood potassium levels while being treated with Korlym (mifepristone), ... Read more

April 16, 2019

High Cortisol Levels in Subclinical Cushing’s Syndrome Patients Linked to Risk of Metabolic Disease, Study Suggests

News

Elevated cortisol levels in people with subclinical Cushing’s syndrome appear to increase their likelihood of metabolic disease — a group of factors that raise the risk of heart disease — ... Read more

April 11, 2019

Cyclic Cortisol Production May Lead to Misdiagnosis in Cushing’s, Study Finds

News

Increased cortisol secretion may follow a cyclic pattern in patients with adrenal incidentalomas, a phenomenon that may lead to misdiagnosis, a study reports. Since cyclic subclinical hypercortisolism may increase ... Read more

April 9, 2019April 9, 2019

Changes in Salivary Cortisol May Help Diagnose Cushing’s Disease

News

Changes in salivary cortisol after desmopressin stimulation could be a supplementary tool in the diagnosis of Cushing’s disease, according to Brazilian researchers. Their study, “Desmopressin Stimulated Salivary Cortisol as a Supplementary Tool in ... Read more

April 4, 2019

Breast Cancer Treatment Lapatinib May Have Role as Cushing’s Syndrome Therapy, Pre-clinical Study Shows

News

Blocking the EGFR signaling pathway using the breast cancer treatment lapatinib significantly reduces the amount of adrenocorticotropic hormone (ACTH) produced by pituitary tumor cells and their proliferation in mice, ... Read more

April 2, 2019

Phase 2 Trial to Assess Osilodrostat as Treatment for Children with Cushing’s Disease

News

Novartis is launching a Phase 2 trial to assess the safety and efficacy of its investigational therapy osilodrostat — an inhibitor of cortisol synthesis — in children with Cushing’s disease. ... Read more

March 28, 2019

Recorlev Continues to Show Meaningful Improvements, Phase 3 Trial Shows

News

Strongbridge Biopharma‘s Recorlev (levoketoconazole) continues to show clinically meaningful improvements in the control of cortisol among patients with endogenous Cushing’s syndrome, a Phase 3 clinical trial shows. Cushing’s syndrome is caused ... Read more

March 26, 2019

Cushing’s Disease Study Shows Importance of Confirming Diagnosis

News

The annual incidence of Cushing’s disease in Sweden increased between 2005 and 2013 compared to earlier periods, according to nationwide data. However, this could be because of factors other than ... Read more

March 21, 2019

Recorlev Safe, Effective Over Long Term for Treatment of Cushing’s, Phase 3 Data Suggest

News

Long-term treatment with Strongbridge Biopharma‘s Recorlev (levoketoconazole) continues to be well-tolerated and to induce clinically meaningful improvements in endogenous Cushing’s syndrome patients, an extended evaluation of a Phase 3 clinical trial shows. Cushing’s ... Read more

March 19, 2019

Etomidate Well-tolerated and Effective in Cushing’s Syndrome Patients, Case Series Suggests

News

Etomidate, a commonly used anaesthetic, is well-tolerated and can be used in low doses to reduce cortisol levels in patients with Cushing’s syndrome, a report of three cases suggests. The ... Read more

Pin It on Pinterest